# AZD4635 Relative Bioavailability Study

> **NCT03710434** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 21 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** AZD4635 50 mg nano-suspension (reference)
- **DRUG:** AZD4635 solid oral formulation - fasted
- **DRUG:** AZD4635 solid oral formulation - fed
- **DRUG:** Lansoprazole and AZD4635 50 mg solid oral formulation
- **DRUG:** AZD4635 solid oral formulation variant 1 - fasted
- **DRUG:** AZD4635 solid oral formulation variant 2 - fasted
- **DRUG:** [14C] AZD4635 IV microtracer - fasted

## Key facts

- **NCT ID:** NCT03710434
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-01
- **Primary completion:** 2019-04-02
- **Final completion:** 2019-04-02
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2020-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03710434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03710434, "AZD4635 Relative Bioavailability Study". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03710434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*